G lioblastoma has one of the worst prognoses of any neoplasm, with a median overall survival of 6-14 months and a 2-year survival rate of 15%-26%. 16, 17 Factors that are correlated with survival include tumor size and location (supratentorial and cerebellar), age at presentation, Karnofsky Performance Scale (KPS) score at presentation, treatment modality, histological findings, and O 6 -methylguanine-DNA methyltransferase (MGMT) methylation status. 18, 20 Over the years, there have been several anecdotal reports of postoperative infection conferring improved survival in patients with glioblastoma, but there have been few studies providing data to substantiate this claim. There have been 2 retrospective studies investigating the effect of postoperative infections on survival in patients with glioblastoma. Bohman et al.
small sample sizes available in the current retrospective studies, the aim of our study was to provide a more comprehensive investigation of the subject using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, which provides more nationally representative data and a larger sample size. Our intent was to perform a retrospective comparison of patients with glioblastoma with or without postoperative infections and assess its impact on survival.
Methods

Data Source
We used the linked database SEER-Medicare. SEER is a national database that includes cancer cases with cancer details (such as tumor details, first course of treatment, number of cancers, survival, mortality and cause, etc.) along with patient characteristics and demographics. The Medicare part contains different claims of different health services used with associated payments. Thus, the SEERMedicare database is restricted to data of the elderly (age 65 or older) with cancer. Each patient in the database has a unique identifier that is used to link to different data files. SEER-Medicare is available, for a fee, to researchers on a project-to-project basis.
Our SEER-Medicare is a tailored database, containing patients with primary brain tumors from 1997 to 2010 with their Medicare claims. Our Medicare part is composed of the Medicare Provider Analysis and Review file, the outpatient claims file, the Physician/Supplier Part B file, the Durable Medical Equipment file, and the Hospice file.
Inclusion and Exclusion Criteria and Patient Selection
The inclusion criteria of the study were as follows: 1) histology codes 94403, 9441/3, or 9442/3, with concurrent topology codes C71.0-C71.4; 2) age 66 years or older at diagnosis to allow for 1 full year retrospective review; 3) microscopically confirmed resection-craniotomy (ICD-9 codes 01.24, 01.25, 01.31, 01.32, 01.39, 01.51, 01.53, 01.59; CPT code 61304) or biopsy (ICD-9 codes 01.11-01.14, 01.18; CPT4 code 61140); 4) having both part A and part B Medicare during the period from 1 month before diagnosis until death or until December 31, 2010; and 5) having age as the only reason for Medicare entitlement.
The exclusion criteria were: 1) a diagnosis of other primary tumors within 1 year of diagnosis; 2) not having surgery; or 3) unknown or missing surgery status according to SEER. Also, patients for whom the surgery or biopsy was not found in the Medicare part in the period from 15 days before the diagnosis date to 2 months after were excluded. Enrollment in a health maintenance organization (HMO) at any time from 1 month before diagnosis until death or December 31, 2010, was also cause for exclusion.
The time of diagnosis was obtained from the SEER database. The SEER database dates only contain the month and the year. Therefore, we assumed the day of diagnosis as the 15th day of the month. Then, we adjusted all the analyses to take into account this 15-day error.
Patient characteristics were mainly obtained from the SEER database. Characteristics considered were the age at diagnosis, the race and sex of the patient, and the extent of surgery. Some characteristics were extracted from the Medicare part. Characteristics included were comorbidities such as the Gagne score, having diabetes, smoking status, having prior craniotomy, and whether a patient underwent a reoperation within 30 days or had complications within 30 days of diagnosis. The Gagne score is a comorbidity score that was developed to include both the Charlson score and the Elixhauser score. It was found to outperform each of the other scores individually. 4 Smoking status was recognized by the presence of ICD-9 code 305.1 and diabetes by ICD-9 code 250.
Explanatory Variables and Outcome Variable
The testing variable was whether the patient developed infection or not. We considered bacterial meningitis (ICD-9 codes 320-320.9), nonbacterial meningitis (ICD-9 codes 321-321.8, 322-322.9), intracranial abscess (ICD-9 code 324.0), and postoperative infection (ICD-9 codes 998.5, 998.59, and 998.51) as positive for infection. Other explanatory variables were patient characteristics and demographics described above. The outcome variable was survival. Survival was counted in months from 15 days from diagnosis until death or until censoring on December 31, 2010.
Statistical Analysis
Data were summarized using means and standard deviations as well as medians and interquartile ranges (IQRs) for continuous variables, and number and percentage for categorical variables. Patient characteristics and demographics were compared with the Wilcoxon rank-sum test for continuous variables and the chi-square test for categorical variables.
The impact of infection on survival was first assessed using univariate analysis. Kaplan-Meier curves were used to display survival, then the survival times were compared using the log-rank test. A multivariate analysis was also performed using the proportional hazards method, with infection status as the testing variable and controlling for age, race, sex, extent of initial surgery, Gagne score, diabetes, smoking status, and whether the patient had previous craniotomies. All tests were 2-sided and a p value < 0.05 was considered significant. All data preprocessing and analysis was performed in SAS 9.4 (SAS Institute).
Results
Using the SEER-Medicare database, a total of 3784 patients with glioblastoma from 1997 to 2010 were identified. Of these patients, 3670 had at least 1 month of survival. One hundred fifty-four patients (4.2%) had infection (defined as bacterial or nonbacterial meningitis, intracranial abscess, or postoperative infection by ICD-9 coding) within the 1st month of surgery. Postoperatively, 3516 (96%) had no evidence of any infection. When compared with patients with no infections, patients who had infections had no significant difference in age, Gagne comorbidity score, race, extent of surgery (defined by local, partial, or gross-total resection), diabetic status, and smoking status (Table 1 ). There was a lower percentage of patients in the infection group that was female at 37.0%, compared with 47.3% in the no-infection group (p = 0.013).
Having an infection did not appear to affect survival in patients who experienced an infection within 1 month of glioblastoma resection, with a median survival of 5 months in the infection group compared with 6 months in the no-infection group, resulting in a hazard ratio (HR) of 1.114 (95% confidence interval [CI] 0.945-1.313), and a p value of 0.17 (Table 2 ). Age (HR 1.050), average Gagne comorbidity score (HR 1.063), and having diabetes (HR 1.175) did appear to correlate with worse survival, whereas extent of surgery, race, smoking status, and whether the patient had previously undergone a craniotomy did not affect survival ( Table 2 ). The Kaplan-Meier survival curve is shown in Fig. 1 .
Discussion
Although postoperative infections have been considered historically to have a negative impact on both morbidity and mortality in surgical patients, anecdotal evidence, as well as recent case reports and retrospective studies, have indicated the possibility that postoperative infection in patients with glioblastoma may have a protective effect on long-term survival. A literature search found 9 patients in case reports or case series with intracranial tumors that had prolonged survival associated with postoperative infections. 2, 8, 11, 12, 19 Of these case reports, only 2 patients had glioblastoma, with others having high-grade (III or above) astrocytomas.
Prior to our study, there have only been 3 retrospective cohort studies investigating the impact of postoperative infection on survival in patients with glioblastoma. 1 Eighteen patients had bacterial infections, and of these, 17 had gram-positive infections. These cases were then compared with age-matched cohorts. Overall, a statistically insignificant survival advantage was observed in the infection group (Kaplan-Meier, p = 0.27). Interestingly, when patients whose infections occurred late in their courses were removed from the analysis, the advantage in mean survival disappeared. Early infection was defined in the paper as infections in the first half of the postoperative survival period compared with total survival time.
In 2011, De Bonis et al. studied 197 patients with glioblastoma and identified 10 (5.08%) with postoperative bacterial infection. 3 They showed that the infection group had a median survival of 30 months, compared with 15 months for patients without infection. They also showed that patients who underwent subtotal resection and had a KPS score of 70 or lower was negatively associated with survival.
In addition to the 2 retrospective studies on the effect of bacterial infection on survival in patients with glioblastoma, there was a study by Rahbar et al. in 2012 that examined the effect of low-grade human cytomegalovirus (HCMV) infection on survival.
14 Brain tumor tissue sections from consecutive patients with glioblastoma who survived more than 18 months (n = 40) were examined. Sixteen (40%) of the 40 patients with glioblastoma who lived more than 18 months had a low-grade HCMV infection, whereas only 3 (8%) of 40 patients who lived less than 18 months did (p = 0.0006). The authors concluded that low-grade HCMV infection was strongly associated with long-term survival in patients with glioblastoma.
Our study is the first large-scale database study (n = 3784) to examine the effect of postoperative infection on survival in patients with glioblastoma. In patients with glioblastoma who had infections within 1 month of surgery, there was no difference in survival between the infection (median survival 5 months) and no-infection (median 6 months) groups (p = 0.17). We also showed that older age, increased Gagne comorbidity score, and having diabetes may be negatively associated with survival. Our results are consistent with those of the Bohman et al. study, which ultimately showed that postoperative infection did not confer any survival advantage in patients with glioblastoma. 1 Although several studies have now shown that postoperative infection does not confer a survival benefit in patients with glioblastoma, there continues to be speculation in the neurosurgical community to the contrary. Several theories have been proposed in the past to explain why postoperative infection may lead to improved survival.
De Bonis et al. 3 theorized that it may be due to antagonistic proliferation of the bacteria, as in local competition for resources between the tumor cells and the replicating microorganisms. Another theory proposed by Bohman et al. 1 and other authors is that infection in the tumor bed may stimulate the patient's immune response, thereby serving as a form of endogenous immunotherapy against glioblastoma cells. Additionally, Burt Vogelstein's laboratory reported an interesting study where they first injected CT26 (colon) and RENCA (renal carcinoma) into 47 mice, and then introduced the anaerobic bacterium Clostridium novyi-NT into the animals and found that 30% of mice treated with such spores were cured of their cancers. The authors also concluded that the effect was immune mediated, because cured animals rejected a subsequent challenge of the same tumor. 16 In particular, other authors have postulated that tumor necrosis factor-a, a factor secreted in response to infection, may be involved in cytotoxic cellmediated tumor suppression. 5, 7, 13 Interestingly, there are also some other studies outside the neurosurgical literature pointing to a possible link between infection and survival in malignancies. Ruckdeschel et al. retrospectively reviewed 18 patients with lung carcinoma complicated by postoperative empyema. 15 The 5-year survival rate for the empyema group was 50%, compared with 18% for the control group of 34 patients. Another study by Jeys et al. found that patients with osteosarcomas who had postoperative infection after endoprosthetic surgery had a survival rate of 84.5% at 10 years (n = 41), compared with 62.3% in the noninfected group (n = 371; p = 0.017). 7 They showed that infection was an independent prognostic factor on Cox regression analysis. Finally, in the veterinary literature Lascelles et al. examined 47 dogs with osteosarcoma of the distal radius 9 and showed that the dogs with an infection were less likely to die, with an HR of 0.446.
There are several limitations of this study. The sensitivity and specificity of the patients identified in our study depend on the accuracy of input in the SEER-Medicare database; coding practices likely vary by hospital and various factors may influence coding. 6, 10 Additionally, the The lack of granularity also makes it difficult to determine the specific organism causing the infection, or the specific type of postoperative infection, as we were only able to break down the infections into bacterial, nonbacterial, intracranial abscess, or postoperative infection by ICD-9 coding.
Conclusions
Despite its limitations, this study used the large number of records available in the SEER-Medicare database to provide a national view of the effect of postoperative infection on survival in patients with glioblastoma. Overall, there was no difference in survival for patients with glioblastoma who had infections within 1 month postoperatively. However, given the persistent interest in the possibility of postoperative infections conferring survival in patients with glioblastoma, as well as studies outside the neurosurgical literature showing potential survival benefit, further retrospective and even prospective large-scale studies are needed that allow for greater granularity, to further investigate this important question.
